Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company... Show more
a developer of therapeutic products based on cell adhesion
Industry Biotechnology
A.I.dvisor indicates that over the last year, FENC has been loosely correlated with AMLX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To FENC | 1D Price Change % | ||
|---|---|---|---|---|
| FENC | 100% | -3.00% | ||
| AMLX - FENC | 37% Loosely correlated | -3.51% | ||
| RZLT - FENC | 37% Loosely correlated | -1.69% | ||
| REPL - FENC | 35% Loosely correlated | +1.59% | ||
| COGT - FENC | 34% Loosely correlated | -1.34% | ||
| IPHA - FENC | 34% Loosely correlated | -2.45% | ||
More | ||||
On September 22, 2026, the Stochastic Oscillator for FENC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In 58 of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Following a +3.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in 204 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
FENC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FENC as a result. In 91 of 112 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for FENC turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
FENC moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FENC crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FENC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for FENC entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.050) is normal, around the industry mean (26.780). P/E Ratio (64.143) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.963) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.